Review maps synthetic-lethality targets in MTAP-deficient, MSI-high, and CCNE1-amplified cancers
Background
A review has surveyed synthetic-lethality strategies that target vulnerabilities arising from cancer-cell genetic alterations. Published in the ASCO Educational Book, it describes targets under development for MTAP-deficient cancers, microsatellite instability-high (MSI-high) tumors, and CCNE1-amplified tumors. It does not report the performance of an original screening experiment or treatment outcomes from a single clinical trial.
Synthetic lethality occurs when a cell can survive a single genetic defect, but its viability decreases when two different genetic alterations are present together. This can lead to strategies that target a vulnerability paired with a genetic alteration already present in a cancer cell. Abnormalities in pathways once considered difficult to target directly with drugs can thus serve as starting points for therapeutic strategies.
The review describes applications in DNA damage response (DDR), epigenetic alterations, and changes in cellular metabolism and proliferation. It discusses the clinical success of approved PARP inhibitors in patients with BRCA-mutated cancers as a precedent supporting the clinical potential of this approach.
Key findings
The authors explain that advances in high-throughput drug screening and CRISPR-Cas9 screening have helped identify synthetic-lethal vulnerabilities in cell lines that may be drug targets. These discoveries are leading to the development of related drugs and biomarkers for predicting treatment response. Biomarkers can help determine which patients with particular genetic features should be considered for treatment.
The review pairs tumor genetics with specific development strategies. For MTAP-deficient cancers, it discusses MTA-cooperative PRMT5 inhibitors and MAT2A inhibitors; for MSI-high tumors, WRN inhibitors; and for CCNE1-amplified tumors, PKMYT1 inhibitors and WEE1 inhibitors. The central approach is to match a vulnerability to a specific genetic alteration.
This list does not mean that these drugs have already demonstrated efficacy in each patient group. The abstract says emerging approaches are in late preclinical development and/or early clinical trials. It does not provide the exact development stage of each candidate, patient numbers, response rates, or comparator results. The available information therefore does not allow efficacy comparisons among targets or a judgment that one strategy is superior.
Significance and outlook
The review considers the precedent set by approved PARP inhibitors alongside new synthetic-lethality strategies being evaluated, and organizes development directions by genetic subgroup. It offers researchers an overview of which tumor features and drug targets might be linked when designing follow-up studies.
Whether vulnerabilities identified in cell lines translate into patient benefit remains to be established separately. The suggestion that predictive biomarkers could help select patients should not be read as evidence that the clinical efficacy of strategies under development has been established. The available abstract does not allow assessment of the toxicity, resistance, duration of benefit, or detailed trial conditions for individual strategies. The current evidence describes development directions; it does not support the establishment of new standards for personalized treatment.
The source is the bibliographic record and abstract of the ASCO Educational Book review “Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology.” DOI: 10.1200/edbk-26-517160. This information was checked against the provided Europe PMC bibliographic record and abstract.
Cancer Discovery, Published May 2026. DOI: [Source Generated Data]
Summary: Bypassing the historical operational challenges that render major oncogenic drivers undruggable, this study systems high-throughput drug profiles integrated with systematic CRISPR-Cas9 screening infrastructure. By scaling comparative loss-of-function cascades across genomic networks, the platform maps precise synthetic lethal interactions across key hallmarks of cancer, including the DNA damage response (DDR) and cellular metabolism pathways. The framework refines multivariate predictive biomarkers of response, establishing a validated computational baseline capable of directing precise patient selection in the clinic. Mirroring the conceptual validation provided by approved PARP inhibitors, this approach delivers a scalable computational matrix to accelerate targeted biological discovery and prospective human clinical translation.
Cancer drug development teams can use this review as a research map linking genetic alterations to candidate targets. For example, when planning development for MTAP-deficient cancers, they could consider PRMT5 and MAT2A inhibition strategies and use the review as a starting point for checking the patient populations and endpoints of relevant clinical trials. WRN in MSI-high tumors and PKMYT1 and WEE1 in CCNE1-amplified tumors fit the same framework. However, the genetic features listed in the abstract alone cannot establish eligibility for a particular trial or whether a treatment can be prescribed. Teams must additionally check each trial’s selection criteria and efficacy and safety data. The results with approved PARP inhibitors should not be generalized to the effects of other targets still in development.